CTIS2023-506735-15-00招募中1 期
MT-7117-A-302 Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria - MT-7117-A-302
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Subjects provided written informed consent to participate. For minor subjects, both minor’s assent and legal representative´s consent will be required., Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical history., Subjects aged 12 years to 75 years, inclusive, at Screening., Subjects are willing and able to travel to the study sites for all scheduled visits., In the Investigator’s opinion, subject can understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel and receiving direct sunlight exposure as much as possible)., Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug., Female subjects of childbearing potential and male subjects with partner of childbearing potential currently using/willing to use 2 effective methods of contraception
排除标准
- •History or presence of photodermatoses other than EPP or XLP., Previous treatment with any investigational agent such as bitopertin within 12 weeks before Screening OR 5 half-lives of the investigational product (whichever is longer)., Subjects who are unwilling or unable to go outside in sunlight during daylight hours most days (e.g., between 1-hour post-sunrise and 1 hour pre-sunset) during the study., Use of sunscreens with zinc oxide., Presence or history of any hepatobiliary disease, including drug-induced liver injury at screening, determined as clinically significant by the Investigator after the discussion with the Sponsor Medical Monitor., Subjects with Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP) = 2.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening., History (in the last 2 years) or presence of alcohol abuse, or abuse of illicit drugs in the opinion of the Investigator., History of melanoma., Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi cannot be resolved through biopsy or excision, the subject will be excluded from the study., History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects., Presence of clinically significant acute or chronic renal disease or subjects with an estimated glomerular filtration rate (eGFR) <60 mL/min as calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation (2021) for adults and by the Schwartz creatinine equation for adolescents (2009). Modification of Diet in Renal Disease can be used for adults per local recommendations., Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects., Female subjects who are pregnant, lactating, or intending to become pregnant during the study., Treatment with any of the following medications or therapy within each period before Randomization (Visit 2): - Afamelanotide within 3 months; - Phototherapy within 3 months; - Cimetidine within 4 weeks; - Antioxidant agents within 4 weeks; - Chronic treatment with any scheduled analgesic agents., Dermatological treatments with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects at screening such as, for example, tanning agents., Subjects who participated in any previous MT-7117 clinical studies.
研究者
相似试验
未知
3 期
ONO-7847 Phase 3 StudyJPRN-jRCT2080220800ONO PHARMACEUTICAL CO.,LTD.344
进行中（未招募）
不适用
ALFA 0703 : A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Chemotherapy or azacitidine as salvage therapy and Azacitidine as Maintenance Therapy in Older Patients with Acute Myeloblastic Leukemia (AML) - ALFA 0703EUCTR2006-005562-39-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
未知
2 期
ONO-2745 IIb/III StudyPatients undergoing surgery requiring general anesthesiaJPRN-jRCT2080221928ONO PHARMACEUTICAL CO.,LTD.325
进行中（未招募）
1 期
This study is for research purposes only to test plitidepsin for patients requiring hospitalization due to COVID-19.moderate COVID-19 infectionMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2020-005951-19-BGPharma Mar, S.A.609
进行中（未招募）
1 期
This study is to determine the efficacy and safety of Two Dose Levels of Plitidepsin compared with the group of control for patients requiring hospitalization due to COVID-19.EUCTR2020-005951-19-ESPharma Mar, S.A.205